EnVision Endoscopy Announces Oversubscribed Series A Financing and Reaches First 50 Patient Procedures with SimpleStitch™ Suturing System

WALTHAM, Mass., Nov. 10, 2026 /PRNewswire/ -- EnVision Endoscopy, Inc., a medical technology company developing innovative solutions for gastrointestinal (GI) endoscopic surgery, today announced the successful closing of an oversubscribed $11.5 million Series A financing and the completion of its first 50 patient procedures using the SimpleStitch™ Suturing System.

Together, these milestones mark a significant step in the company's transition from technology development to clinical adoption and commercial expansion, supporting its mission to make endoscopic suturing more accessible to physicians performing minimally invasive gastrointestinal procedures.

Designed for use with standard flexible endoscopes, the SimpleStitch™ Suturing System is intended to help physicians with an intuitive approach and easy-to-use technology to perform endoscopic suturing. The technology is designed to address longstanding challenges associated with tissue closure following advanced gastrointestinal endoscopic procedures, potentially expanding access to suturing beyond specialized expert centers.

EnVision received FDA clearance for the SimpleStitch™ Suturing System in 2025 and initiated a limited U.S. market release in 2026. The completion of the first 50 patient procedures represents an important milestone in building clinical experience, strengthening physician partnerships, and advancing the company's commercial strategy.

"Technologies to simplify endoscopic resection are coming, and closure should be even simpler. SimpleStitch™ bridges the gap between conventional clips and advanced endoscopic suturing, making strong, confident tissue closure more accessible. I'm excited that 50 procedures have now been safely completed at pilot sites in 2026. This is an important step toward bringing better closure options to physicians and their patients," said Dr. Andrew Storm of Atrium Health Wake Forest Baptist, who performed the first-in-human procedure with SimpleStitch™.

"We founded EnVision to address persistent challenges in endoscopic surgery. Reaching our first 50 patient procedures validates the work of our team and physician collaborators in bringing SimpleStitch™ into clinical practice. Combined with our Series A financing, this milestone positions us to build on that momentum and bring our technology to more physicians and patients," said Azadeh Khanicheh, Ph.D., Co-Founder and Chief Executive Officer of EnVision Endoscopy.

Series A Financing to Support Commercial Expansion
The oversubscribed $11.5 million Series A financing was led by Puma Venture Capital, with participation from UTEC – University of Tokyo Edge Capital, existing investor Olympus Corporation of the Americas, and MassVentures.

"Puma backs minimally invasive technologies that can improve both labor productivity and how well patients do. SimpleStitch™ takes endoscopic suturing out of a handful of expert centers and puts it on the scope a physician already owns. More endoscopists can close with confidence, more patients get a less invasive option, and that's why we led this round," said Amit Hazan, Co-Founder and Managing Partner of Puma Venture Capital.

The financing will support EnVision Endoscopy's next phase of growth, including expanded commercial availability, physician training, clinical evidence generation, manufacturing scale-up, and further product development.

The strong investor participation reflects confidence in EnVision Endoscopy's technology, its approach to addressing unmet needs in gastrointestinal endoscopic surgery, and the growing opportunity to advance minimally invasive endoscopic interventions.

Addressing a Growing Need for Endoscopic Closure
Endoscopy is steadily replacing surgery for a growing range of gastrointestinal conditions. More than 20 million gastrointestinal endoscopic procedures are performed in the U.S. each year, and advanced resection techniques such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and peroral endoscopic myotomy (POEM) are being adopted rapidly in the U.S. and Europe. Each of these procedures can leave defects that need secure closure.

The endoscopic closure device market is projected to grow 7–8% annually through the end of the decade. Yet endoscopic suturing remains concentrated in a small number of expert centers, because existing systems require extensive training and dedicated equipment. SimpleStitch™ is designed to close this gap by bringing suturing to the broader community of endoscopists using the endoscopes they already have.

About EnVision Endoscopy, Inc.
EnVision Endoscopy, Inc. is a Waltham, Massachusetts-based medical technology company developing innovative devices for gastrointestinal endoscopic surgery. Co-founded by Azadeh Khanicheh, Ph.D., and Christopher C. Thompson, MD, MSc, the company is focused on addressing unmet clinical needs through technologies that support less invasive endoscopic procedures.

Its SimpleStitch™ Suturing System is designed to facilitate endoscopic suturing and tissue approximation using standard flexible endoscopes. EnVision's mission is to advance endoscopic surgery through practical, innovative technologies that serve physicians and patients.

For more information, visit: www.envisionendoscopy.com

SOURCE ENVISION ENDOSCOPY INC.